Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 17.99 as of 2026-09-12T00:15:25.379Z.
Consensus retrieved: 2026-09-11T00:19:03.716Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-09-12T00:15:25.379Z.
Quote observation: 2026-09-11T20:00:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 851a10a4f804764db129068cfd25610262a8e8385927960445e436e8f9c334b3
Forward PE Ratio (17.99) = Dated Quote Price ($321.57) / Consensus Forward EPS ($17.88)
FORWARD PE RATIO
17.99
SECTOR MEDIAN · HEALTHCARE
18.95
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
-5.09%
vs the sector median at left
Cencora, Inc.
Market Cap
$62.57B
Forward PE Ratio
17.99
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Cencora, Inc. (COR) | $62.57B | 17.99 |
| Boston Scientific Corporation (BSX)vs › | $63.88B | 13.07 |
| Moderna, Inc. (MRNA)vs › | $57.13B | N/A |
| Cardinal Health, Inc. (CAH)vs › | $54.94B | 18.70 |
| Cigna Corporation (CI)vs › | $74.19B | 9.20 |
| Humana Inc. (HUM)vs › | $49.21B | 44.77 |
| Becton, Dickinson and Company (BDX)vs › | $49.00B | 14.04 |
| Edwards Lifesciences Corporation (EW)vs › | $48.58B | 28.11 |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $80.51B | 14.40 |
| Teva Pharmaceutical Industries Limited (TEVA)vs › | $43.20B | 18.72 |
Trailing P/E
23.9
reported TTM EPS
Forward P/E
18.0
consensus EPS · fiscal year ending 2026-09-30
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $17.88 implies +32.8% EPS growth vs the reported trailing $13.46.
At the dated quote price of $321.57, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-09-30 | $17.88 | $17.86 – $17.91 | 8 | 18.0x |
| 2027-09-30 | $19.81 | $19.48 – $20.12 | 7 | 16.2x |
| 2028-09-30 | $21.93 | $19.84 – $24.47 | 3 | 14.7x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
